These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38502338)

  • 21. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
    Fisher MJ; Shih CS; Rhodes SD; Armstrong AE; Wolters PL; Dombi E; Zhang C; Angus SP; Johnson GL; Packer RJ; Allen JC; Ullrich NJ; Goldman S; Gutmann DH; Plotkin SR; Rosser T; Robertson KA; Widemann BC; Smith AE; Bessler WK; He Y; Park SJ; Mund JA; Jiang L; Bijangi-Vishehsaraei K; Robinson CT; Cutter GR; Korf BR; ; Blakeley JO; Clapp DW
    Nat Med; 2021 Jan; 27(1):165-173. PubMed ID: 33442015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study.
    Suenobu S; Terashima K; Akiyama M; Oguri T; Watanabe A; Sugeno M; Higashimori M; So K; Nishida Y
    Neurooncol Adv; 2023; 5(1):vdad054. PubMed ID: 37287695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Efficacy of Mek Inhibitors in the Treatment of Plexiform Neurofibromas: A Retrospective Study.
    Cacchione A; Fabozzi F; Carai A; Colafati GS; Baldo GD; Rossi S; Diana M; Megaro G; Milano GM; Macchiaiolo M; Crocoli A; De Ioris MA; Boccuto L; Secco DE; Zama M; Agolini E; Tomà P; Mastronuzzi A
    Cancer Control; 2023; 30():10732748221144930. PubMed ID: 36598023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Plexiform Neurofibromas with MEK Inhibitors: First Results with a New Therapeutic Option.
    Vaassen P; Dürr NR; Rosenbaum T
    Neuropediatrics; 2022 Feb; 53(1):52-60. PubMed ID: 34905788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical impact of selumetinib on pediatric elephantiasis neuromatosa.
    Blegen K; Ortiz-Romero SE; Juarez O; Voeller J
    Pediatr Dermatol; 2022 Sep; 39(5):764-766. PubMed ID: 35739628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open-label study.
    Wang Z; Zhang X; Li C; Liu Y; Ge X; Zhao J; Yuan X; Li Q
    Clin Transl Med; 2024 Mar; 14(3):e1589. PubMed ID: 38456222
    [No Abstract]   [Full Text] [Related]  

  • 27. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
    Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ
    J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selumetinib: the first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma.
    Mukhopadhyay S; Maitra A; Choudhury S
    Curr Med Res Opin; 2021 May; 37(5):789-794. PubMed ID: 33683166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
    Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
    Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.
    Weiss B; Widemann BC; Wolters P; Dombi E; Vinks AA; Cantor A; Korf B; Perentesis J; Gutmann DH; Schorry E; Packer R; Fisher MJ
    Pediatr Blood Cancer; 2014 Jun; 61(6):982-6. PubMed ID: 24851266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
    Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
    Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment With Selumetinib for Café-au-Lait Macules and Plexiform Neurofibroma in Pediatric Patients With Neurofibromatosis Type 1.
    Guo YX; Wang HX; Wang SS; Croitoru D; Piguet V; Gao XH; Xu XG
    JAMA Dermatol; 2024 Mar; 160(3):366-368. PubMed ID: 38198164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of Cardiac Function by Echocardiographic Global Longitudinal Strain in a Cohort of Children with Neurofibromatosis Type 1 Treated with Selumetinib.
    Caiffa T; Tessitore A; Magnolato A; Petz M; Bobbo M; Chicco D; D'Agata Mottolese B; Porcari A; Barbi E; Sinagra G; Bruno I
    Paediatr Drugs; 2023 Mar; 25(2):217-224. PubMed ID: 36529809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
    Weiss B; Widemann BC; Wolters P; Dombi E; Vinks A; Cantor A; Perentesis J; Schorry E; Ullrich N; Gutmann DH; Tonsgard J; Viskochil D; Korf B; Packer RJ; Fisher MJ
    Neuro Oncol; 2015 Apr; 17(4):596-603. PubMed ID: 25314964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selumetinib side effects in children treated for plexiform neurofibromas: first case reports of peripheral edema and hair color change.
    Baldo F; Magnolato A; Barbi E; Bruno I
    BMC Pediatr; 2021 Feb; 21(1):67. PubMed ID: 33549085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acneiform rash as a side effect of selumetinib in a child with neurofibromatosis type 1 treated for inoperable plexiform neurofibromas: Good results with doxycycline.
    Volontè M; Isoletta E; Gordon S; Foiadelli T; Bassanese F; Rossi A; Marseglia GL; Savasta S; Brazzelli V
    Dermatol Ther; 2022 Aug; 35(8):e15607. PubMed ID: 35638252
    [No Abstract]   [Full Text] [Related]  

  • 37. Management of neurofibromatosis type 1-associated plexiform neurofibromas.
    Fisher MJ; Blakeley JO; Weiss BD; Dombi E; Ahlawat S; Akshintala S; Belzberg AJ; Bornhorst M; Bredella MA; Cai W; Ferner RE; Gross AM; Harris GJ; Listernick R; Ly I; Martin S; Mautner VF; Salamon JM; Salerno KE; Spinner RJ; Staedtke V; Ullrich NJ; Upadhyaya M; Wolters PL; Yohay K; Widemann BC
    Neuro Oncol; 2022 Nov; 24(11):1827-1844. PubMed ID: 35657359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current status of MEK inhibitors in the treatment of plexiform neurofibromas.
    Gross AM; Dombi E; Widemann BC
    Childs Nerv Syst; 2020 Oct; 36(10):2443-2452. PubMed ID: 32607696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selumetinib for children with plexiform neurofibromas.
    Burki TK
    Lancet Oncol; 2017 Feb; 18(2):e69. PubMed ID: 28089105
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
    Widemann BC; Babovic-Vuksanovic D; Dombi E; Wolters PL; Goldman S; Martin S; Goodwin A; Goodspeed W; Kieran MW; Cohen B; Blaney SM; King A; Solomon J; Patronas N; Balis FM; Fox E; Steinberg SM; Packer RJ
    Pediatr Blood Cancer; 2014 Sep; 61(9):1598-602. PubMed ID: 24753394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.